Bragar Eagel & Squire, P.C. Is Investigating Phathom, TuSimple, Mercury Systems, and Cassava and Encourages Investors to Contact the Firm

New York, New York, UNITED STATES


NEW YORK, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), TuSimple Holdings, Inc. (NASDAQ: TSP), Mercury Systems, Inc. (NASDAQ: MRCY), and Cassava Sciences, Inc. (NASDAQ: SAVA). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)

On August 2, 2022, before market hours, Phathom issued a press release entitled “Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates” which announced that “we detected trace levels of a nitrosamine in vonoprazan drug product in our post-approval testing as we prepared for commercial launch.” Further, the press release announced that “[t]he Company is working with the FDA and plans to obtain approval of and implement an additional test method, specification, including a proposed acceptable intake limit, and additional controls to address this impurity prior to releasing our first vonoprazan-based products to the market.” Finally, the Company announced that “[t]hese additional activities will result in a delay of the planned VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK product launches.”

On this news, Phathom’s stock price fell $2.61 per share, or 28%, to close at $6.46 per share on August 2, 2022.

For more information on the Phathom investigation go to: https://bespc.com/cases/PHAT

TuSimple Holdings, Inc. (NASDAQ: TSP)

TuSimple is the subject of a Wall Street Journal article published on August 1, 2022. The article alleges that one of the Company’s autonomously driven trucks left its lane of travel without warning before striking a cement barricade. The article states that the accident “underscores concerns that the autonomous-trucking company is risking safety on public roads in a rush to deliver driverless trucks to market.” Although the Company attempted to blame human error, the Journal points out that “it was the autonomous-driving system that turned the wheel and that blaming the entire accident on human error is misleading.” The article also reveals that the Federal Motor Carrier Safety Administration has launched a “safety compliance investigation.”

Based on this news, shares of TuSimple fell $0.97, or 9.7%, during intraday trading to close at $8.99 per share on August 1, 2022.

For more information on the TuSimple investigation go to: https://bespc.com/cases/TSP

Mercury Systems, Inc. (NASDAQ: MRCY)

The investigation concerns whether Mercury and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

On July 26, 2022, Glasshouse Research (“Glasshouse”) published a short report entitled “Roll-Up Mercury Systems Set to Unravel.”  The Glasshouse report claimed, among other things, that Mercury’s organic revenue is “overstated,” that the Company’s recent Physical Optics acquisition has been a “disaster,” and that management has prematurely recognized revenue on certain significant projects. 

On this news, Mercury’s stock price fell $4.73, or 7.6%, during intraday trading on July 26, 2022.

For more information on the Mercury investigation go to: https://bespc.com/cases/MRCY

Cassava Sciences, Inc. (NASDAQ: SAVA)

On April 18, 2022, The New York Times published an article entitled “Scientists Question Data Behind an Experimental Alzheimer’s Drug.”  The article addressed Cassava’s experimental Alzheimer’s drug, simufilam, and reported that one of Cassava’s advisers, Dr. H.Y. Wang, had five papers he authored retracted from the scientific journal PLoS One after an in-depth investigation revealed “serious concerns about the integrity and the reliability of the results.” 

On this news, Cassava’s stock price fell sharply during intraday trading on April 19, 2022.

For more information on the Cassava investigation go to: https://bespc.com/cases/SAVA

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com